Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Proteomics01:33

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abnormal B-Cell Exosome Proapoptotic and Antiapoptotic Cargo in Multiple Sclerosis: Potential Implication in Progressive Disease Biology.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

The Multiple Sclerosis Severity Allele rs10191329<sup>A</sup> and Cognitive Function: A UK Biobank Study.

Annals of clinical and translational neurology·2026
Same author

Morbidity and mortality outcomes of surgical versus transcatheter aortic valve replacement in patients dependent on dialysis.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Proteomic Age Acceleration in Multiple Sclerosis Precedes Symptom Onset and Associates with Severity.

medRxiv : the preprint server for health sciences·2026
Same author

Antibody-Negative Nivolumab-Induced Autoimmune Encephalitis: A Case Report and Review of Seronegative Presentations.

Cureus·2026
Same author

Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds.

Neurology·2026

Related Experiment Video

Updated: May 23, 2026

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

Genetic-Proteomic Integration Identifies Predictive Plasma Proteins for Multiple Sclerosis.

Yuan Ding1,2, Dylan Hamitouche1, Simon Thebault1,3

  • 1The Neuro (Montreal Neurological Institute-Hospital), Montréal, Canada.

Annals of Neurology
|May 22, 2026
PubMed
Summary
This summary is machine-generated.

Identifying early multiple sclerosis (MS) biomarkers is crucial. This study used proteogenomic integration to find plasma proteins linked to MS risk and predict disease onset, offering potential for early detection.

Related Experiment Videos

Last Updated: May 23, 2026

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

Area of Science:

  • Genetics and proteomics
  • Immunology
  • Neuroscience

Background:

  • Multiple sclerosis (MS) has a prolonged preclinical phase, necessitating early biomarkers for risk stratification and intervention.
  • Identifying circulating proteins associated with MS susceptibility can improve early detection and management.

Purpose of the Study:

  • To identify plasma proteins driving MS susceptibility using proteogenomic integration.
  • To evaluate the prediagnostic predictive value of these proteins for MS incidence and their association with disease severity.

Main Methods:

  • Utilized cis-acting protein quantitative trait loci (pQTL) for 2,545 plasma proteins in a large cohort.
  • Employed Mendelian randomization and colocalization to assess MS risk associations.
  • Validated candidate biomarkers in prediagnostic samples for predicting incident MS and disease severity.

Main Results:

  • Identified 39 proteins associated with MS risk, enriched in immune and viral pathways, particularly B-cell related.
  • Eight genetically implicated proteins predicted time to MS diagnosis in prediagnostic samples.
  • DKKL1 showed protective associations across risk, incidence, and severity; 13 novel risk loci were nominated.

Conclusions:

  • An integrated genetic-proteomic framework identified causal proteins and refined MS risk loci.
  • Findings support the development of genetically anchored biomarkers for preclinical MS detection and intervention.
  • This approach holds translational potential for early disease management.